Our whole‐genome CRISPR‐Cas9 knockout (KO) screen in NRASQ61R melanoma cells revealed the Kelch domain‐containing F‐Box protein 42 (FBXO42), an E3 ubiquitin ligase (Sun et al., 2009), involvement in resistance toward trametinib treatment. Here, FBXO42 is linked to melanoma.